BioNexus Gene Lab Corp. has secured a substantial financing facility of $500 million in an Equity Purchase Agreement with ARC Group International Ltd.. This agreement grants BioNexus discretionary access to capital over a period of 36 months, aimed at advancing its precision oncology, contract development and manufacturing (CDMO) services, and therapeutic development initiatives throughout Southeast Asia.
The funding is expected to play a critical role in the commercial rollout of the VitaGuard minimal residual disease (MRD) platform, as well as in the enhancement of regional CDMO services. BioNexus Gene Lab detailed that the facility provides a long-term capital source to support various strategic projects, including the implementation of high-value bioprocessing and manufacturing services.
Under the terms of the agreement, BioNexus may issue and sell registered common stock to ARC over the specified 36-month duration. In exchange for ARC’s commitment, BioNexus has issued 175,000 shares at a closing price of $4.32 on November 26, 2025. Notably, ARC is limited to owning no more than 9.99% of BioNexus’s outstanding shares and is prohibited from short-selling or hedging the company’s securities. Furthermore, shares cannot be sold until a registration statement has been filed.
Strategic Expansion and New Initiatives
“This commitment from ARC strengthens our capital position at a pivotal time for BioNexus Gene Lab,” said Sam Tan, Chief Executive Officer of the company. He emphasized the importance of the financing in light of the company’s licensing agreement for the VitaGuard MRD platform and its transition into a CDMO capable of supporting advanced bioprocessing and manufacturing capabilities. Tan indicated that the facility is designed to back milestone-driven initiatives vital for the company’s growth.
In addition to the financing, BioNexus recently established a licensing agreement with Fidelion Diagnostics to commercialize the VitaGuard assay across Malaysia, Singapore, Indonesia, and Thailand. This innovative platform aims to facilitate early cancer detection, recurrence monitoring, and informed treatment decision-making. The newly acquired capital is intended to bolster clinical adoption and regulatory efforts associated with this important technology.
The company is also broadening its CDMO services, which encompass biologics production and assay manufacturing. The financing facility is expected to support investments in quality systems, expand manufacturing capacity, and enhance technical capabilities to align with global contract manufacturing standards. Additionally, the funds may assist in progressing the company’s partnership initiative with BirchBioMed for FS2, a promising therapeutic candidate targeting fibrosis, hypertrophic scarring, and skin regeneration.
Through these developments, BioNexus Gene Lab is positioning itself for significant growth in the rapidly evolving fields of biotechnology and diagnostics, with substantial implications for healthcare in the region.
